Global peritoneal dialysis market was valued at USD 4.4 billion in 2021, and it is expected to reach a value of USD 6.39 billion by 2028, at a CAGR of more than 6.2% over the forecast period (2022–2028).
Westford, USA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- As the population grows older, the demand for Peritoneal Dialysis Market is rapidly increasing. Peritoneal dialysis is a type of kidney treatment that uses peritoneal fluid to clean and remove waste from the blood. This treatment is typically used to treat people with kidney failure, but it can also be used to treat other types of diseases. When people need peritoneal dialysis, it can be difficult to find a facility that can provide the service.
There are currently over 23,000 facilities around the global peritoneal dialysis market that provide peritoneal dialysis services. This number is expected to grow by 10% each year. This growth is due in part to the aging population and the increasing number of people who have kidney failure. In many cases, peritoneal dialysis is an excellent choice for people who cannot have a kidney transplant or who are on the waiting list for a kidney.
Get sample copy of this report:
https://skyquestt.com/sample-request/peritoneal-dialysis-market
Increasing Prevalence of Lifestyle Associated Diseases and Kidney Failure
According to the National Kidney Foundation, kidney failure is on the rise and unfortunately, it’s not just a problem confined to older adults. In fact, the increase in kidney failure rates has been seen in both children and adults across all races and genders in the global peritoneal dialysis market. As per SkyQuest’s analysis, 1 in 3 Americans are at risk of kidney failure, which translates to around 80 million people in the single country. On a global level, 23% of the global population are at risk of kidney failure and around 10% are suffering from kidney failure already, which is around 720 million people across the globe.
The incidence of kidney failure is on the rise, in part due to obesity and lack of exercise. The US Centers for Disease Control and Prevention (CDC) reports that between 2001 and 2021, the incidence of kidney failure increased by 134%. The increase is in the peritoneal dialysis market most commonly seen in those over the age of 60. CDC further stated that the incidence of kidney failure has increased by about 50% over the past two decades, and it is now the ninth leading cause of death in the United States.
There are several genetic and lifestyle factors that can further increase the risk for kidney failure, including being overweight or obese, having high blood pressure, smoking, and drinking excessive amounts of alcohol. In addition, chronic diseases such as diabetes can also cause kidney failure. It is found that around 30% of all cases of kidney failure cases in the peritoneal dialysis market are caused due to diabetes. This problem becomes even more severe as people age, as diabetes often progresses faster in older patients.
There are a few reasons for this increase. One reason is that more people are reaching old age, which means there are more people getting kidney failure.
Browse summary of the report and Complete Table of Contents (ToC):
https://skyquestt.com/report/peritoneal-dialysis-market
Home Based Peritoneal Dialysis is on the Rise to Save Cost over Hemodialysis
The popularity of home-based peritoneal dialysis (HBPD) is on the rise, as its costs are beginning to exceed those of hemodialysis (HD). In a recent study, it was found in the global peritoneal dialysis market that patients who underwent HBPD spent an average of $5,890 more than those who underwent HD over a six-year period. This disparity is likely due to the fact that HBPD requires implantation of a dialysis catheter directly into the peritoneum (the abdominal wall), which can be more costly than HD's use of an external catheter. Despite this expense, however, HBPD is increasingly being favored over HD because it has a significantly lower mortality rate and is better at treating certain types of kidney failure.
On the other hand, SkyQuest found that patients are more likely to save around 11% on their HBPD than in-center hemodialysis across US peritoneal dialysis market. This further spurred the popularity and adoption of patients especially above 65 years. It has been observed that in the last few years, the Americans spent on average over $110,000 on HD than $93,000 on PD. Moreover, HD had over 71% higher drug cost than the PD, which further costs around 35% higher for rehabilitation for HD.
The average cost of HBPD is only around $3,000 per year, which is much lower than the $10,000 or more per year that traditional dialysis costs. Moreover, because HBPD is done at home, it can be done on a regular basis (every other day or every three days) which means that it can be a very affordable way to manage chronic kidney disease in the peritoneal dialysis market. In addition, HPD has a few advantages over traditional dialysis. For example, it can be done during bed rest which means that it is easier for people to comply with the treatment regimen.
SkyQuest has published a report on global peritoneal dialysis market. It covers detailed understanding about current market trends, consumer behavior, their spending power on peritoneal dialysis per cycle, and average cost per cycle by region and country, among others.
Government of India is Taking Steps to Improve Access to Peritoneal Dialysis
The government of India is taking steps to improve access to peritoneal dialysis for rural population as more than 220,000 are being diagnosed with some kind of kidney diseases in the India peritoneal dialysis market, causing additional demand for 34 million recycles. Currently, India has over 1,900 nephrologists, which translates to 1 behind 1.9 million people. In addition, India is likely had world’s largest diabetic population by 2030. Moreover, India has the organ donation rate of only 0.01%, which further compels the patients to opt for dialysis.
To overcome the shortage of experts and provide timely treatment, the Indian government has already started strengthening its healthcare infrastructure. The National Dialysis Program (NDP) provides peritoneal dialysis in select hospitals across the country. So far, the NDP has reached over 1 lakh patients in rural areas. The program aims to provide dialysis 3 times a week to patients with end-stage renal disease who are not able to access it due to geographical and economic constraints in country’s peritoneal dialysis market.
In 2016 and 2020, the Indian Ministry of Health and Family Welfare commissioned a study to determine the feasibility of investing in peritoneal dialysis facilities in rural areas. The study found that there was a strong demand for peritoneal dialysis services in rural areas, and that such facilities could be successfully launched with government support. As a result, earlier this year, the Indian Ministry announced to invest around $225 million under AYUSHMAN BHARAT scheme in peritoneal dialysis facilities over the next five years. This investment will help to expand access to peritoneal dialysis across India’s vast rural regions.
Speak to Analyst for your custom requirements:
https://skyquestt.com/speak-with-analyst/peritoneal-dialysis-market
Top Development in India peritoneal Dialysis Market
Indian Government have planned to add at least on dialysis center across 750 districts
In August 2022, State Government of Kolkata announced its plan to starts peritoneal dialysis center in rural areas to avoid suffering of people coming from remote areas to urban areas for the treatment, which is expected to the regional peritoneal dialysis market growth
In February 2022, State Government of Kerala, India opened free peritoneal dialysis center across 11 district to save cost and time for patients
Increased dialysis coverage from $19 per cycle to $23 per cycle
SkyQuest has tracked all the developments by countries in global peritoneal dialysis market. The report would provide insights about prevalence, demand, supply, government regulation, policies, agenga, and planning to overcome burgeoning demand for PD. In addition to this, the report provides data of patient population, required PD cycles per year, impact of chronic diseases like obesity and diabetes on overall demand for PD.
Key Players in Global Peritoneal Dialysis Market
B. Braun Melsungen AG (Germany)
Fresenius Medical Care AG (Germany)
Asahi Kasei Medical Co., Ltd. (Japan)
Related Reports in SkyQuest’s Library:
Global Next Generation Sequencing Market
Global 3D Cell Culture Market
SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.
Email: sales@skyquestt.com
LinkedIn Facebook Twitter
The FDA is convening an adcomm meeting of its Pulmonary-Allergy Drugs Advisory Committee, slated for October 6, to discuss Veru Inc's (NASDAQ: VERU) request for Emergency Use Authorization of sabizabulin for hospitalized COVID-19 patients at high risk for ARDS. In a public notice, the FDA said that as part of the adcomm, one of the focuses of the experts will include "the treatment effect size in the context of the high placebo mortality rate, the limited size of the safety database, and identif
Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.
When planning for the future, health care ranks as one of the highest concerns for both savers and retirees alike. Not only are health care costs rising by more than 5% every year, but rampant inflation and volatile market performances … Continue reading → The post New Bill May Allow Penalty-Free 401(k) Withdrawals for This Retirement Expense appeared first on SmartAsset Blog.
Jefferies upgrades the stock and other analysts raise their price targets on Regeneron following better-than-expected data on a new formulation of the company's signature eye medication.
These strategies can help you reduce your health care costs.
Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.
Shares of Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) climbed 160.4% this week, according to data from S&P Global Intelligence. The stock closed at $14.90 last Friday and then opened this Tuesday at $12.16. The stock began trading on Aug. 31 after its initial public offering (IPO).
Relay Therapeutics Inc's (NASDAQ: RLAY) ReFocus trial for RLY-4008 was published on the European Society for Medical Oncology's (ESMO) website. The abstract has been selected for an oral presentation at the upcoming ESMO Congress 2022. Relay Therapeutics is evaluating RLY-4008, its bile duct cancer drug, for a narrow group of patients with FGFR2-altered cholangiocarcinoma. Related: Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial. Potent efficacy was observed across all dos
Parkinson's disease (PD) may be an issue that stems from the health and function of your brain, according to the National Institute on Aging. However, a new study recently published by JAMA Network Open also reveals a connection between eating habits and mortality rates for those with PD.In a study titled "Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease," researchers took a look at 1,251 participants who were previously diagnosed with Parkin
Amgen's biosimilar drug is close to stealing away sales from AstraZeneca's rare disease drug called Soliris.
An emerging crop of drug developers is using artificial intelligence, machine learning, and sometimes supercomputers to design safer and more effective drugs. The latest update from Relay Therapeutics provides early validation for a technology-enabled approach. At the very least, the preliminary data published ahead of an important scientific meeting shows the promise of the company's unique strategy to design more selective drug candidates.
Amylyx Pharmaceuticals Inc. shares were riding high in the first few hours of trading following a key FDA advisory committee's positive vote on its first drug, despite the unusual caveats that accompanied the vote.
It seems like every major technology company wants to disrupt healthcare. It's easy to see why as the United States spends nearly 18% of its gross domestic product (GDP) on healthcare. "...Because national health expenditures are projected to grow 1.1 percentage points faster than gross domestic product per year on average over 2019-28, the health share of the economy is projected to rise from 17.7% in 2018 to 19.7% in 2028."
AstraZeneca plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) announced long-term follow-up results from the Phase 3 PAOLA-1 and SOLO-1 trials in first-line advanced ovarian cancer evaluating Lynparza (Olaparib) as a combination and monotherapy. The companies said the data represents the longest-term data for any PARP inhibitor in this setting. The Phase 3 PAOLA-1 trial evaluated Lynparza combined with bevacizumab as first-line maintenance therapy. Final overall survival (OS) in Lynparza plus bev
A Pennsylvania woman is claiming that she spent four days in the hospital after biting into a scrap of metal in her chicken fries order from Burger King.
Scott Taylor never got to move on from COVID-19. The analysis was based on data from 20 major U.S. hospital systems, including more than 1.3 million adults with a COVID diagnosis and 19,000 with a long COVID diagnosis between May 2020 and July 2022.
It's not the first time authorities have put millions of people under strict restrictions with no end in sight, and all for case-load numbers that dwarf other nations.
The White House is pushing Americans to get the updated Covid booster ahead of a potential fall surge of the virus. The new shots target the BA.5 omicron subvariant.
Medicare is designed to help eligible individuals pay for healthcare. One of the most important decisions to make when enrolling for the first time or making changes to your coverage during open enrollment is whether to opt for Medicare Advantage … Continue reading → The post Medicare Open Enrollment Is Almost Closed: Medicare Advantage vs. Medicare appeared first on SmartAsset Blog.